A protein called LMCD1 is present at higher levels in the lungs of patients with interstitial lung disease (ILD) linked to systemic sclerosis (SSc) than in healthy individuals, and may be a candidate target for the treatment of the disease, a small study suggests. Researchers found that the…
News
The active ingredient of EHP-101, a cannabidiol-derived medicine being developed by Emerald Health Pharmaceuticals (EHP), can set in motion a tissue’s response to low oxygen or hypoxia, which backs its use for treating systemic sclerosis (SSc) and multiple sclerosis (MS), a study in cells and mice found.
People with systemic sclerosis (SSc) show higher levels of certain antibodies against the Epstein-Barr virus, which is suggestive of dormant viral infections becoming reactivated in these patients, a new study shows. The study, “Detection of Epstein–Barr virus in systemic sclerosis patients: A molecular and serological based…
The first two groups of patients have been enrolled in a Phase 2a clinical trial that’s testing the cannabidiol-derived medication EHP-101 in people with systemic scleroderma (SSc), the therapy’s developer Emerald Health Pharmaceuticals (EHP) announced. Interim results are expected next year, according to EHP. Participants are currently…
The release of CXCL10 — an inflammatory signaling molecule associated with a worse prognosis in scleroderma — from connective tissue cells and those lining blood vessel walls was significantly weakened with iloprost, a recent study reports. These findings showcase the added benefits of iloprost, commonly used to widen blood vessels…
The case of a 14-year-old boy with diabetes provided a starting point for a finding of juvenile systemic sclerosis (SSc): the limited joint mobility evident in the boy’s fingers can be an initial sign of underlying SSc, the report’s researchers suggested. Although “the coexistence of diabetes with juvenile systemic sclerosis…
Being male is linked with a higher risk of mortality among patients with scleroderma, irrespective of the type of autoantibody they carry, according to an analysis from two large databases. The study, “Sex-specific risk of anti-topoisomerase antibodies on mortality and disease severity in systemic sclerosis: 10-year…
The levels of certain metabolites — molecules that take part in metabolism — circulating in the blood may help differentiate pulmonary arterial hypertension (PAH) due to scleroderma (SSc-PAH) from idiopathic PAH, a new study shows. The “metabolic signature” correlated with worse disease severity in PAH tied to SSc.
A protein called Thy-1 is present at higher levels in the skin of patients with systemic sclerosis (SSc) than in healthy skin, and the more Thy-1, the worse the disease, a study has found. When researchers modeled the disease in lab animals, they observed that mice lacking Thy-1 had…
The experimental therapy MT-7117 reduces lung inflammation, skin fibrosis (scarring), and blood vessel impairment in a mouse model of systemic sclerosis (SSc), a study found. “MT-7117 demonstrates disease-modifying effects in preclinical models of SSc,” the researchers wrote. “The results of the present study suggest that MT-7117 is a potential…
Recent Posts
- Certain antibodies tied to poorer outcomes in systemic sclerosis
- Dexamethasone reduces inflammation, scarring in SSc mouse model: Study
- Survival improves for SSc-PAH patients on combination therapy
- Combination drug therapy boosts lung, skin health in SSc patients
- On choosing medicine’s side effects over scleroderma progression
- Telerehabilitation improves hand mobility in scleroderma women
- Molecular pathway ID’d as key driver of scarring in scleroderma
- Limited hand function disrupts daily life for people living with SSc
- Coping with loss is part of living with scleroderma
- CAR T-cell therapy eases SSc symptoms, early trial data show